Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296276 · ClinicalTrials.gov registry record · NA
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
A NA study of Type 1 Diabetes Mellitus, sponsored by i-SENS.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT07296276 is a NA study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by i-SENS. The registered enrollment target is 32 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07296276, a NA study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by i-SENS.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.
Conditions Studied
Interventions
- DEVICE CareSens Air 3 primary insertion
- DEVICE CareSens Air 3 secondary insertion
Study Locations (4)
California
- Headlands Research AMCR - Escondido
- Diablo Clinical Research - Walnut Creek
Georgia
- Atlanta Diabetes Associates - Atlanta
Washington
- Rainier Clinical Reseach Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07296276
The ClinicalTrials.gov registry entry for NCT07296276 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (77% lower). The listed sponsor is i-SENS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which CareSens Air 3 primary insertion is the first listed.
NCT07296276 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Washington.
Frequently Asked Questions
What is clinical trial NCT07296276 about?
NCT07296276 is a clinical study titled "Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM". This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1 diabetes.
What is the current status of trial NCT07296276?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2026-02-09. Estimated completion is 2026-04-30.
What conditions does trial NCT07296276 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT07296276?
The interventions under investigation include: CareSens Air 3 primary insertion (DEVICE), CareSens Air 3 secondary insertion (DEVICE).
Who is sponsoring clinical trial NCT07296276?
This trial is sponsored by i-SENS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07296276 being conducted?
This trial has 4 study locations across California, Georgia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
-
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.